Charles River Laboratories | CRL - Nettoeinkommen

Aktienkurs
162.85
Täglich Wechseln
-5.84 -3.46%
Monatlich
-9.18%
Jährlich
17.20%
Q2 Prognose
173.94




Nettoeinkommen Veränderung Datum
Agilent USD 305M 129M 2025-12
Align Technology USD 112.77M 22.99M 2026-03
Bio-Rad Laboratories USD 720M 1.06B 2025-12
Bruker USD 3.5M 22.5M 2026-03
Cardinal Health USD 399M 68M 2026-03
Charles River Laboratories USD -14.84M 261.71M 2026-03
Cigna USD 1.65B 420M 2026-03
Concord Medical Services Hldg CNY -27.14M 63.85M 2025-06
CVS Health USD 2.94B 0 2026-03
Danaher USD 1.03B 168M 2026-03
Dentsply International USD -10M 136M 2026-03
Elevance Health USD 1.76B 1.22B 2026-03
Humana USD 1.19B 1.98B 2026-03
Illumina USD 134M 200M 2026-03
Incyte USD 303.33M 4.05M 2026-03
IQVIA Holdings USD 274M 240M 2026-03
Laboratory Of America USD 277.8M 113.1M 2026-03
Lakefront Biotherapeutics EUR 14.49M 767.65M 2026-03
Lonza CHF 426M 119M 2025-06
McKesson USD 1.68B 496M 2026-03
Merck EUR 319M 583M 2025-12
Mettler Toledo International USD 169.45M 116.31M 2026-03
Novartis USD 3.16B 747M 2026-03
Pfizer USD 2.69B 4.34B 2026-03
Quest Diagnostics USD 251M 6M 2026-03
Revvity USD 40.72M 57.65M 2026-03
Thermo Fisher Scientific USD 1.65B 313M 2026-03
United Therapeutics USD 274.9M 89.4M 2026-03
UnitedHealth USD 6.28B 6.27B 2026-03
Veradigm USD -59.82M 74.35M 2022-12
Waters USD -72M 297.21M 2026-03
West Pharmaceutical Services USD 138.8M 6.7M 2026-03